

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10697655
	Filing Date		2003-10-31
	First Named Inventor	Michael Weller	
	Art Unit	1615	
	Examiner Name	Klinkel, Kortney L.	
Attorney Docket Number		NGIO-001	

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	6127393		2000-10-03	FERNANDEZ	
	2	6407125		2002-06-18	FERNANDEZ	
	3	6407139		2002-06-18	ISAJI	

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1	20020128290		2002-09-12	OHSHIMA ETSUO	
	2	20050239892		2005-10-27	MEYDANI	
	3	20060011443		2006-05-25	FUKUSHIMA	

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS						Remove
--------------------------	--	--	--	--	--	--------

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10697655
Filing Date	2003-10-31
First Named Inventor	Michael Weller
Art Unit	1615
Examiner Name	Kinkel, Kortney L.
Attorney Docket Number	NGIO-001

Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1	2 495 952	CA		2004-03-04	KISSEI PHARMACEUTICAL		<input type="checkbox"/>
	2	1369114	EP		2002-06-07	TERNESS		<input type="checkbox"/>
	3	2003-026575	JP		2003-01-29	ROHTO PHARMA		<input type="checkbox"/>
	4	2005-089345	JP		2003-09-16	TENDOU		<input type="checkbox"/>
	5	2006/053390	WO		2006-05-26	ANGIOGEN PHARMACEUTICALS		<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button [Add](#)

NON-PATENT LITERATURE DOCUMENTS

[Remove](#)

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵
	1	AZUMA, H. et al. (1976) "Pharmacological properties of N-(3',4'-dimethoxycinnamoyl) anthranilic acid (N-5), a new anti-atopic agent." Br. J. Pharmac.58: 483-488.	<input type="checkbox"/>
	2	FALLARINO, F., et al, "T cell apoptosis by tryptophan catabolism", Cell Death and Differentiation, 2002, 9 (10):1069-1077	<input type="checkbox"/>
	3	MOFFETT, JR et al. (2003) "Tryptophan and the immune response" Immunology and Cell Biology 81(4):247-265.	<input type="checkbox"/>

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10697655
Filing Date	2003-10-31
First Named Inventor	Michael Weller
Art Unit	1615
Examiner Name	Kinkel, Kortney L.
Attorney Docket Number	NGIO-001

4	PLATTEN, M. et al (2005) "Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite," Science 310 850-855.	<input type="checkbox"/>
5	SHIGEKI, S. et al. (1997) "Treatment of Keloid and Hypertrophic scars by iontophoretic transdermal delivery of tranilast." Scan J. Reconstr Hand Surg. 31(2):151-158.	<input type="checkbox"/>
6	TERNESS, P.; et al, "Inhibition of allogeneic T cell proliferation by indoleamine-2, 3-dioxygenase-expressing dendritic cells: Mediation of suppression by tryptophan metabolites", Journal of Experimental Medicine, 19 August 2002, 196 (4):447-457.	<input type="checkbox"/>
7	WIDNER, B., et al, "Tryptophan degradation to control T-cell responsiveness", Immunology Today, May 2000, 21 (5):250.	<input type="checkbox"/>
8	WIRLEITNER, B., et al., "Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects", Current Medicinal Chemistry, 2003, 10(16):1581-1591.	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.